ELTX
Elicio Therapeutics, Inc.
There isn't enough reported data to score ELTX yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ELTX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ELTX's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ELTX PE Valuation
ELTX has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ELTX Forward outlook
There aren't enough analyst estimates for ELTX to show an outlook.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ELTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.83 | +$1.37 |
| Q2 2026 | -$2.13 | +$1.86 |
| Q1 2026 | -$2.36 | +$1.61 |
| Q4 2025 | -$2.58 | +$1.67 |
| Q3 2025 | -$3.20 | +$3.08 |
| Q2 2025 | -$3.99 | +$2.17 |
| Q1 2025 | -$3.97 | +$3.99 |
| Q4 2024 | -$4.25 | +$4.06 |
ELTX has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ELTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2022 | $653K | +21% |
| Q1 2022 | $1.6M | +344% |
| Q4 2021 | $25.9M | +5552% |
| Q3 2021 | $1.5M | +77% |
| Q2 2021 | $540K | -26% |
| Q4 2020 | $459K | -34% |
HIMS has the stronger quarterly revenue trend. Revenue is down 100% for ELTX versus up 49% for HIMS.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2022 | -1384% | +1995 points |
| Q1 2022 | -879% | +4496 points |
| Q4 2021 | 56% | +3074 points |
| Q3 2021 | -1079% | +322 points |
| Q2 2021 | -3379% | -1010 points |
| Q1 2021 | -5374% | N/A |
| Q4 2020 | -3017% | -978 points |
| Q3 2020 | -1401% | N/A |
ELTX's operating margin was −1384% last quarter, up 1995 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ELTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$10.4M | +$722K |
| Q1 2026 | -$11.6M | -$1.5M |
| Q4 2025 | -$6.8M | +$2M |
| Q3 2025 | -$11.1M | -$3.8M |
| Q1 2025 | -$10.1M | +$2M |
| Q4 2024 | -$8.8M | +$1.1M |
| Q3 2024 | -$7.3M | -$2M |
| Q1 2024 | -$12.1M | -$4M |
ELTX has burned cash in almost every quarter: −$37M over the past year, against −$37M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ELTX on cash generation, producing positive trailing cash flow while its opponent burns cash.
ELTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +37% | +7M shares |
| 1 year | +58% | +9.6M shares |
| 3 years | +773% | +23.3M shares |
| 5 years | +1021% | +23.9M shares |
| Available history | +792% | +23.3M shares |
ELTX has 26M diluted shares, up 58% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q4 2020 | $36,000 |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ELTX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ELTX Net Leverage
ELTX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ELTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.3 | Neutral |
| Stochastic | 13.2 | Oversold |
ELTX's weekly RSI is 33 (neutral) and its Stochastic is 13 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ELTX PE vs Healthcare Sector
ELTX has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ELTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.73 | 9.8% below |
| 20 week MA | $2.40 | 35% below |
| 50 week MA | $6.77 | 77% below |
| 100 week MA | $7.49 | 79% below |
HIMS has stronger trend alignment. ELTX is above 0 of 4 weekly averages versus HIMS above 0 of 5.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ELTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $5.91 | $8.34 | +41% |
| 2024 | $8.34 | $5.15 | -38% |
| 2025 | $5.15 | $8.07 | +57% |
| 2026 YTD | $8.07 | $1.56 | -81% |
ELTX is down 81% so far in 2026, after finishing higher in two of the previous three years.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over ELTX on returns for 2026, with the stronger performance.